By Alex Verayo, Terra Universal
Many manufacturers face the challenge of maintaining sterile products and processes. In most cases, there's no one-size-fits-all solution. Highly effective sterilization technologies, like ethylene oxide gas or hydrogen peroxide vapor, carry substantial risk and often come at a high cost.
The majority of pharmaceutical tablets on the market are film-coated, which serves several purposes, including taste-masking, dissolution modification, and the protection of active pharmaceutical ingredients (APIs) against air, moisture, and light.
The expanding global pharmaceutical industry projects a 4% to 6% annual growth and forecasts that it will reach a value of $1T by 2014. The figures are impressive, yet they place significant pressure on pharmas to bring to market innovative drugs and novel drug delivery systems in order to be part of the growth. Faced with that pressure, many pharmas are streamlining their supply chain to focus on their core competencies and bring products to market faster.
Pharmaceutical X-ray technology can be used for many applications, but Bosch has harnessed the power of the X-ray and used it to accurately determine capsule fill weight and to inspect capsules for defects.
With the growing trend of life sciences companies utilizing contract research organizations (CROs) for the vast majority of clinical trials, now more than ever has documentation become more complex, and it is essential that companies find a documentation solution which will reduce risk and meet compliance requirements.
The underlying science behind the development and use of human pluripotent stem cells has advanced to the point of being able to provide stem cell lines that can reproduce many tissues of the human body. We spoke to a number of scientists on the cutting edge of stem cell research and found that they echoed two common concerns with regard to transporting these highly precious and perishable specimens globally by traditional methods such as dry ice.
Pharmaceutical secondary manufacturing has long stood in stark contrast to the drug discovery end of the business, as well as to other sectors, when it comes to innovation such as continuous manufacturing. Is that about to change? Siemens' Rebecca Vangenechten and Ivo Backx argue that the coming decade could see secondary manufacturing not just catch up but leapfrog other sectors, and that mindset will be a crucial factor.